Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
- Japan, South Korea Sign MOU for Regulatory Affairs
August 21, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- PMDA, AMED Ink Pact to Spur Commercialization of Novel Drugs
August 20, 2015
- PAFSC’s 2nd Committee to Discuss AbbVie’s Combination Drug for Hepatitis C on Aug. 31
August 19, 2015
- PAFSC 2nd Committee to Discuss Orphan Drug Designation for 3 APIs on Aug. 31
August 19, 2015
- 18 Firms Win Approval for Jzoloft Generics, 25 for Exforge Generics
August 18, 2015
- Govt, Pharma Leaders to Meet on Aug. 24 over “Comprehensive Strategy”
August 18, 2015
- FY2016 Drug Pricing Reform
August 18, 2015
- PAFSC First Committee to Review Glatiramer, Add’l Indication for Xarelto on Aug. 28
August 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for July 21 - August 9
August 10, 2015
- MHLW Notifies of Package Insert Changes for Daklinza, Sunvepra
August 10, 2015
- “Greater Emphasis” Will Need to Be Placed on R&D in Field of Oncology: AMED President
August 7, 2015
- MHLW Calls for Package Insert Revision for Inavir, Relenza
August 7, 2015
- Health Minister Reviewing Ways to Strengthen Guidance to Optimize Ethical Drug Ads: Senior Vice Minister Nagaoka
August 6, 2015
- PAFSC 2nd Committee Endorses Approval of AZ’s Vandetanib
August 5, 2015
- Lupus Nephritis to Be Added to Cellcept’s Indication: MHLW Notification
August 4, 2015
- PAFSC’s First Committee Supports Approval of Actelion’s Tracleer for Digital Ulcers in Generalized Scleroderma
August 3, 2015
- AMED Sets Up 5-Step Process to Pick Licensees of Academic Drug Seeds
July 30, 2015
- MHLW to Continue Discussions on Elderly Use of Prevenar 13 under National Vaccination Program
July 29, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…